Print

Patentability, Biosimilars Top Life Sciences Issues for 2012

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

To read the full article click the link below.

Patentability, Biosimilars Top Life Sciences Issues for 2012